HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vorapaxar for the reduction of atherothrombotic events.

Abstract
Vorapaxar is a novel platelet inhibitor that potently and selectively inhibits thrombin-mediated platelet activation without interfering with thrombin-mediated cleavage of fibrinogen via antagonism of the platelet proteinase-activated receptor PAR1. Vorapaxar is a non-peptide himbacine analogue that has been developed for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease.
AuthorsM Diaz-Ricart, G Escolar
JournalDrugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 50 Issue 11 Pg. 747-56 (Nov 2014) ISSN: 1699-3993 [Print] Spain
PMID25525635 (Publication Type: Journal Article)
CopyrightCopyright 2014 Prous Science, S.A.U. or its licensors. All rights reserved.
Chemical References
  • Lactones
  • Platelet Aggregation Inhibitors
  • Pyridines
  • Receptor, PAR-1
  • vorapaxar
Topics
  • Drug Interactions
  • Food-Drug Interactions
  • Humans
  • Lactones (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
  • Platelet Aggregation Inhibitors (therapeutic use)
  • Pyridines (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
  • Receptor, PAR-1 (antagonists & inhibitors)
  • Thrombosis (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: